Laurel M. Lee sold Novo Nordisk A/S (NYSE: NVO)
Laurel M. Lee (R-FL), a U.S. Representative, has disclosed 1 trade in Novo Nordisk A/S (NVO) since 2025, a single sale, worth an estimated $8K in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts).
The trade highlighted here is a sale: Laurel M. Lee sold $1,001 - $15,000 of Novo Nordisk A/S (NYSE: NVO) on May 8, 2025. Since that trade, NVO is down -29.06% against the S&P 500 up +32.78%, an outperformance of -61.84%.
Data updated
Laurel M. Lee's NVO trades vs the price
NVO is down -29.06% since Laurel M. Lee sold on May 8, 2025, versus +32.78% for the S&P 500.
Performance since this trade
All Laurel M. Lee NVO trades
Laurel M. Lee & NVO trading FAQ
Is it legal for Laurel M. Lee to trade Novo Nordisk A/S (NVO) stock?
Yes. Members of Congress are allowed to trade individual stocks, including Novo Nordisk A/S (NVO), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. BullishWhales tracks those disclosures; this page does not imply the trade was improper.
When did Laurel M. Lee sell NVO?
Laurel M. Lee disclosed a sale of $1,001 - $15,000 of Novo Nordisk A/S (NVO) on May 8, 2025, according to public STOCK Act filings.
How has NVO performed since Laurel M. Lee's trade?
Since Laurel M. Lee sold NVO on May 8, 2025, the stock is down -29.06%, versus +32.78% for the S&P 500 over the same period, an outperformance of -61.84%.
How soon must members of Congress disclose a trade?
Under the STOCK Act, members of Congress must publicly report a covered transaction within 45 days of the trade. Filings can still be delayed, amended, or contain errors.
Where can I see all congressional NVO trades?
BullishWhales tracks every disclosed congressional trade in Novo Nordisk A/S (NVO) on the Novo Nordisk A/S congressional trading page, which aggregates filings across all members of Congress.
Laurel M. Lee's NVO tradesAll congressional filings for Novo Nordisk A/SLaurel M. Lee's full profile
Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. Estimated prices and post-trade returns are derived algorithmically from public filings and end-of-day market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.